Moreover, MOL000830 and 2-Aminopurine (2-AP, a known inhibitor of EIF2AK2) share the same binding sites on EIF2AK2: CYS-369, GLN-367, and VAL-281, indicating that MOL000830 can inhibit EIF2AK2 through the same competitive inhibition, exerting anti-AD effects. Here, EIF2AK2 is linked to Alzheimer disease.